Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
13F holders, Q1 2023
Institutional positions in Inozyme Pharma, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 50
- +13 vs. Q4 2022
- Shares held
- 32.0M
- +3.04M (+10.5%) vs. Q4 2022
- Total value
- $183.4M
- +$153.0M (+503.5%) vs. Q4 2022
- New holders
- 18
- 18 more added
- Sold out
- 5
- 5 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 87 | $202.3M |
| Q1 2025 | 97 | $42.5M |
| Q4 2024 | 105 | $145.1M |
| Q3 2024 | 89 | $285.5M |
| Q2 2024 | 90 | $240.1M |
| Q1 2024 | 89 | $382.0M |
| Q4 2023 | 80 | $213.3M |
| Q3 2023 | 77 | $204.6M |
| Q2 2023 | 74 | $190.3M |
| Q1 2023 | 50 | $183.4M |
| Q4 2022 | 37 | $30.4M |
| Q3 2022 | 39 | $82.7M |
| Q2 2022 | 47 | $149.4M |
| Q1 2022 | 50 | $71.2M |
| Q4 2021 | 51 | $118.2M |
| Q3 2021 | 52 | $202.7M |
| Q2 2021 | 50 | $337.1M |
| Q1 2021 | 55 | $379.4M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 60 | $0 | 0.00% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 138 | $791 | 0.00% | +138 | New |
| Wells Fargo & Company | 165 | $945 | 0.00% | +3+1.9% | Added |
| Group One Trading, L.P. | 626 | $3.59K | 0.00% | +626 | New |
| Point72 Middle East FZE | 1,897 | $10.9K | 0.00% | +1,897 | New |
| Simplex Trading, LLC | 4,181 | $23.0K | 0.00% | +4,044+2,951.8% | Added |
| Barclays PLC | 6,273 | $35.9K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 11,548 | $66.2K | 0.00% | +4,443+62.5% | Added |
| Tower Research Capital LLC (TRC) | 14,093 | $81.0K | 0.00% | +10,495+291.7% | Added |
| Charles Schwab Investment Management Inc | 16,549 | $94.8K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 19,356 | $110.9K | 0.00% | +6,210+47.2% | Added |
| Parallel Advisors, LLC | 19,867 | $113.8K | 0.00% | 00.0% | Unchanged |
| Verition Fund Management LLC | 23,900 | $136.9K | 0.00% | +23,900 | New |
| Man Group plc | – | $137.2K | 0.00% | – | New |
| Schonfeld Strategic Advisors LLC | 28,600 | $163.9K | 0.00% | +28,600 | New |
| HRT Financial LP | 45,114 | $258.0K | 0.00% | +45,114 | New |
| Northern Trust Corp | 45,882 | $262.9K | 0.00% | −61−0.1% | Reduced |
| Virtu Financial LLC | 46,995 | $269.0K | 0.03% | +46,995 | New |
| Bank of New York Mellon Corp | 47,165 | $270.3K | 0.00% | +26,922+133.0% | Added |
| Dimensional Fund Advisors LP | 50,577 | $287.0K | 0.00% | +28,370+127.8% | Added |
| Cubist Systematic Strategies, LLC | 50,712 | $290.6K | 0.00% | +50,712 | New |
| Jane Street Group, LLC | 53,525 | $306.7K | 0.00% | +53,525 | New |
| BIT Capital GmbH | 54,226 | $310.7K | 0.05% | +54,226 | New |
| Two Sigma Investments, LP | 65,500 | $375.3K | 0.00% | +53,117+429.0% | Added |
| State Street Corp | 98,055 | $561.9K | 0.00% | +21,700+28.4% | Added |
| Bridgeway Capital Management, LLC | 117,400 | $672.7K | 0.02% | −16,000−12.0% | Reduced |
| Parkman Healthcare Partners LLC | 125,000 | $716.3K | 0.16% | +125,000 | New |
| UBS Oconnor LLC | 147,654 | $846.1K | 0.02% | +147,654 | New |
| Knott David M Jr | 160,000 | $917.0K | 0.39% | +160,000 | New |
| Renaissance Technologies LLC | 186,100 | $1.07M | 0.00% | −72,800−28.1% | Reduced |
| Marshall Wace, LLP | 195,097 | $1.12M | 0.00% | +195,097 | New |
| Overbrook Management Corp | 219,326 | $1.26M | 0.33% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 233,728 | $1.34M | 0.35% | +3,228+1.4% | Added |
| Geode Capital Management, LLC | 241,208 | $1.38M | 0.00% | +8,082+3.5% | Added |
| Laurion Capital Management LP | 271,800 | $1.56M | 0.07% | 00.0% | Unchanged |
| BlackRock Inc. | 451,193 | $2.59M | 0.00% | +24,969+5.9% | Added |
| Samsara BioCapital, LLC | 504,407 | $2.89M | 0.60% | +504,407 | New |
| FMR LLC | 702,996 | $4.03M | 0.00% | +702,996 | New |
| Affinity Asset Advisors, LLC | 751,796 | $4.31M | 1.66% | +251,796+50.4% | Added |
| Citadel Advisors LLC | 793,823 | $4.55M | 0.00% | +793,823 | New |
| Vanguard Group Inc | 1,328,290 | $7.61M | 0.00% | −15,332−1.1% | Reduced |
| CHI Advisors LLC | 1,342,191 | $7.69M | 2.04% | −862,685−39.1% | Reduced |
| Millennium Management LLC | 1,691,075 | $9.69M | 0.01% | +1,393,139+467.6% | Added |
| Sphera Funds Management Ltd. | 1,781,858 | $10.2M | 2.21% | +156,800+9.6% | Added |
| NEA Management Company, LLC | 2,437,689 | $14.0M | 0.97% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 3,213,586 | $18.4M | 7.58% | +552,432+20.8% | Added |
| Rock Springs Capital Management LP | 3,214,900 | $18.4M | 0.44% | +128,873+4.2% | Added |
| Deep Track Capital, LP | 3,250,000 | $18.6M | 0.79% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 3,655,308 | $20.9M | 1.42% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 4,265,138 | $24.4M | 0.05% | +1,165,000+37.6% | Added |
| VR Adviser, LLC | 0 | $0 | 0.00% | −2,709,987−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −37,700−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −11,924−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,834−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −1,381−100.0% | Sold out |